Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution in Children and Adolescents: An 8-Week Phase 3 Study

20260 citationsJournal Articlediamond Open Access

Authors

Teresa Garriga-Baraut · Hebron University

Clara Padró-Casas · Hospital Universitari Germans Trias i Pujol

Adelaida Sánchez Bacallao · Hospital Quirónsalud Barcelona

Pablo Durán-Pérez · Hospital Quirónsalud Barcelona

Eva Lasa Luaces · ENT and Allergy

Porfirio Fernández González · Hospital Universitario Central de Asturias

Amalia Leceta

Abstract

Preservative- and phosphate-free bilastine 0.6% ophthalmic solution with sodium hyaluronate was safe and well-tolerated in pediatric patients aged >2 years after a once-daily, 8-week treatment, with a safety profile comparable to that of placebo.

Topics & Keywords

Ocular Surface and Contact Lens Corneal Surgery and Treatments Ocular Infections and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Investigational Allergology and Clinical Immunology

Volume 37, Issue 3, pp. 0-0

DOI: 10.18176/jiaci.1169

Field-Weighted Citation Impact: 0.00